Peptide vaccines for cancers expressing tumor-associated antigens

• US 8,623,829 B2
• Filed: 05/04/2012
• Issued: 01/07/2014
• Est. Priority Date: 02/21/2007
• Status: Active Grant

• Current Assignee: Oncotherapy Science, Inc.
• Original Assignee: Oncotherapy Science, Inc.
• Inventors: Tsunoda, Takuya, Ohsawa, Ryuji, Yoshimura, Sachiko
• Primary Examiner(s): Huff, Sheela J.
• Application Number:
  US13/464,831
• Publication Number:
  US 20120321649A1
• Time in Patent Office: 613 Days
• Field of Search: None
• US Class Current: 514/19.2
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001122 Ephrin Receptors [Eph]
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/464422 Ephrin Receptors [Eph]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 4/12 from animals; from humans
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value

Abstract

The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

Claims

1. A method of treating a cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of the following (i) and (ii), or a polynucleotide encoding said peptide:

(i) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO;

288; and

(ii) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO;

288 in which 1 or 2 amino acids are substituted.

2. The method of treating cancer of claim 1, wherein the cancer is selected from the group consisting of bladder cancer, cervical cancer, cholangiocellular carcinoma, esophageal cancer, gastric cancer, NSCLC, osteosarcoma, pancreatic cancer, and soft tissue tumor.

3. The method of claim 1, wherein the peptide of (ii) has one or both of the following characteristics:

(a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO;

288 is substituted with methionine; and

(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO;

288 is substituted with valine.

4. A method of treating cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of following (i) and (ii) or a polynucleotide encoding said peptide:

(i) an isolated peptide consisting of the amino acid sequence of SEQ ID NO;

288; and

(ii) an isolated peptide having cytotoxic T cell inducibility, wherein said peptide consists of an amino acid sequence of SEQ ID NO;

288 in which 1 or 2 amino acids are substituted.